Clearance of serum HBsAg and anti-HBs seroconversion following antiviral therapy for chronic hepatitis B

Authors

  • Olivier Borgniet,

    1. INSERM U871, Lyon, France
    2. Hospices Civils de Lyon, Hôtel Dieu, Service d'hépatologie et de gastroentérologie, Lyon, France
    Search for more papers by this author
  • Parviz Parvaz,

    1. INSERM U871, Lyon, France
    2. Hospices Civils de Lyon, Hôpital de la Croix Rousse, Laboratoire de Virologie Nord, Lyon, France
    Search for more papers by this author
  • Cécile Bouix,

    1. INSERM U871, Lyon, France
    2. Hospices Civils de Lyon, Hôtel Dieu, Service d'hépatologie et de gastroentérologie, Lyon, France
    Search for more papers by this author
  • Philippe Chevallier,

    1. INSERM U871, Lyon, France
    2. Hospices Civils de Lyon, Hôpital de la Croix Rousse, Laboratoire de Virologie Nord, Lyon, France
    3. Université Lyon 1, Lyon, France
    Search for more papers by this author
  • Christian Trépo,

    1. INSERM U871, Lyon, France
    2. Hospices Civils de Lyon, Hôtel Dieu, Service d'hépatologie et de gastroentérologie, Lyon, France
    3. Université Lyon 1, Lyon, France
    Search for more papers by this author
  • Patrice André,

    1. Hospices Civils de Lyon, Hôpital de la Croix Rousse, Laboratoire de Virologie Nord, Lyon, France
    2. Université Lyon 1, IFR128 Biosciences Lyon-Gerland, INSERM U871, Lyon, France
    Search for more papers by this author
  • Fabien Zoulim

    Corresponding author
    1. INSERM U871, Lyon, France
    2. Hospices Civils de Lyon, Hôtel Dieu, Service d'hépatologie et de gastroentérologie, Lyon, France
    3. Université Lyon 1, Lyon, France
    • INSERM U871, 151 Cours Albert Thomas, 69424 Lyon Cedex 03, France.
    Search for more papers by this author

Abstract

In this study, we have analyzed the evolution of serum HBsAg levels in 16 patients with chronic hepatitis B who showed an HBsAg seroconversion following antiviral therapy. The data showed that the clearance of serum HBsAg is slower than that of serum HBV DNA, which may reflect a slow kinetics of clearance of infected hepatocytes. Interestingly, HBsAg was detectable for a longer time using the Architect assay than with the Bio-Rad assay. As viremia suppression is achieved in most patients under therapy with the new generation of nucleoside analogs, these data suggest that the quantitative monitoring of serum HBsAg may represent a novel tool for the assessment of antiviral therapy efficacy. J. Med. Virol. 81:1336–1342, 2009. © 2009 Wiley-Liss, Inc.

Ancillary